- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine
- Drug
- Lead sponsor
- Pancreatic Cancer Action Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 361–384
of 1,758
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Allergy, Peanut
- Interventions
- ligelizumab, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 55 Years
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 23 more
- Conditions
- Breast Cancer
- Interventions
- Imatinib, Docetaxel
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 6
- States / cities
- Gainesville, Georgia • Louisville, Kentucky • Baton Rouge, Louisiana + 3 more
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- LAF237 = vildagliptin
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 35 Years to 70 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Ankylosing Spondylitis
- Interventions
- 150 mg open-label secukinumab, 150 mg double-blinded secukinumab, 300 mg double-blinded secukinumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 322 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 65
- States / cities
- Jonesboro, Arkansas • Fullerton, California • Loma Linda, California + 60 more
- Conditions
- Non-Small-Cell Lung
- Interventions
- Canakinumab, Docetaxel, Placebo
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Kansas City, Missouri • The Bronx, New York + 3 more
- Conditions
- Hepatic Impairment
- Interventions
- Alpelisib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Lakewood, Colorado • Miami, Florida • Orlando, Florida + 1 more
- Conditions
- Ovarian Cancer
- Interventions
- Imatinib Mesylate, Docetaxel
- Drug
- Lead sponsor
- Daniela Matei, MD
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 9
- States / cities
- Galesburg, Illinois • Elkhart, Indiana • Evansville, Indiana + 6 more
- Conditions
- Plaque-type Psoriasis
- Interventions
- AIN457, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Pasadena, California + 21 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- vildagliptin, thiazolidinedione (TZD)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 2,665 participants
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Ofatumumab, Covid-19 vaccine
- Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Owosso, Michigan • St Louis, Missouri + 1 more
- Conditions
- Pancreatic Cancer, BRAF Mutant Colorectal Cancer, Melanoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Cancer, Cervical Squamous Cell Cancer, Esophageal Squamous Cell Cancer, Lung Squamous Cell Cancer
- Interventions
- LGK974, PDR001
- Drug · Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2024
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
- Conditions
- Chagas Disease
- Interventions
- LXE408, Placebo, Benznidazole
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 4
- States / cities
- Sylmar, California • Gainesville, Florida • Boston, Massachusetts + 1 more
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Tisagenlecleucel
- Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- AUY922, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • San Antonio, Texas
- Conditions
- Familial Hypercholesterolemia - Homozygous
- Interventions
- Inclisiran, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • St Louis, Missouri + 1 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Ceritinib, Trametinib
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Davis, California • San Francisco, California
- Conditions
- Postoperative Ocular Pain After PRK Surgery
- Interventions
- SAF312, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 4
- States / cities
- Chevy Chase, Maryland • Sioux Falls, South Dakota • Draper, Utah + 1 more
- Conditions
- Acute Gouty Arthritis Flares
- Interventions
- ACZ885, Triamcinolone acetonide 40 mg
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 33
- States / cities
- Anniston, Alabama • Mobile, Alabama • Norwalk, California + 28 more
- Conditions
- Breast Cancer, Lung Cancer
- Interventions
- yttrium Y 90-edotreotide
- Radiation
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Renal Transplantation
- Interventions
- Enteric-coated mycophenolate sodium (EC-MPS), Mycophenolate mofetil, Placebo to mycophenolate sodium, Placebo to mycophenolate mofetil
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 53
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 40 more
- Conditions
- Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hypereosinophilic Syndrome, Systemic Mastocytosis
- Interventions
- Nilotinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 507 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 24
- States / cities
- Duarte, California • Stanford, California • Aurora, Colorado + 20 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- vildagliptin
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 78 Years
- Enrollment
- 544 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Extensive-stage Small Cell Lung Cancer (ES-SCLC)
- Interventions
- DJI136
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 3
- States / cities
- Lexington, Kentucky • Houston, Texas • Seattle, Washington